BNB PLUS CORP
BNBXNASDAQTrading Snapshot
- Day Range
- $0.16 – $0.16
- 52-Week Range
- $0.07 – $7.15
- Volume
- $2.66B
- Avg Volume
- $1.96B
- Shares Outstanding
- 7.2M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-15.47
- Dividend Yield
- —
- Dilution (1yr)
- +21180.0%
Why Investors Own BNBX
- ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BNB PLUS CORP
BNBX
StockOtter · stockotter.spaceAbout BNB PLUS CORP
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Applied Dna Sciences (NASDAQ:BNBX) and Myriad Genetics (NASDAQ:MYGN) Head to Head Analysis
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based
Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based o
BNB Plus Corp. Appoints Three New Directors Identified Through Ongoing Strategic Review
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (OTCQB: BNBX) ("BNB Plus" or the "Company") today announced the appointment of three new members to its Board of Directors, identified as part of the Company's ongoing s
BNB Plus Corp. (BNBX) Announces Transition to Fully Internalized Digital Asset Treasury Management
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (OTCQB: BNBX) ("BNB Plus" or the "Company") today announced that, in furtherance of its ongoing strategic review, it has reached a mutual agreement with Cypress Manageme
BNB Plus Corp. (BNBX) Announces Nasdaq Delisting Determination and Transition to OTCQB Market; Company to Seek Review by Nasdaq Listing and Hearing Review Council
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company") today announced that it has received a delisting determination from the Hearing Panel of the Nasdaq Stock Market LLC ("Nasda